Platforms OMV

Validation of an FFF-MALS Method to Characterize the Production and Functionalization of Outer-Membrane Vesicles for Conjugate Vaccines

An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection

Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis

Describing the pre-clinical data of the candidate Lyme vaccine based on Intravacc’s OMV platform, this study shows that OMV’s expressing Borrelia (lipo)proteins is a promising vaccine concept that might lead to protecting humans against Lyme disease. Currently, no vaccine against Lyme disease, the fastest growing and most common tick-borne illness in North America and Europe,…

Shortening the Lipid A Acyl Chains of Bordetella pertussis Enables Depletion of Lipopolysaccharide Endotoxic Activity

Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines

Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination

Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles

Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis

Immunoproteomic Profiling of Bordetella pertussis Outer Membrane Vesicle Vaccine Reveals Broad and Balanced Humoral Immunogenicity